DaShenLin Pharmaceutical Group Co., Ltd. - Laporan Laba Rugi (TTM)

DaShenLin Pharmaceutical Group Co., Ltd.
CN ˙ SHSE ˙ CNE100002RG2
CN¥ 17.17 ↑0.07 (0.41%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi DaShenLin Pharmaceutical Group Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 13,593 14,583 15,280 15,697 16,446 16,759 17,377 18,425 19,222 21,248 22,518 23,519 24,154 24,531 25,336 25,885 26,539 26,497 26,701 26,674
Change (%) 7.28 4.78 2.73 4.77 1.91 3.69 6.03 4.32 10.54 5.98 4.45 2.70 1.56 3.28 2.16 2.53 -0.16 0.77 -0.10
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 8,358 8,993 9,364 9,600 10,179 10,385 10,659 11,357 11,828 13,226 14,170 14,862 15,309 15,795 16,474 16,976 17,528 17,422 17,587 17,542
Change (%) 7.60 4.12 2.52 6.03 2.03 2.63 6.55 4.15 11.81 7.14 4.88 3.01 3.17 4.30 3.05 3.25 -0.61 0.95 -0.26
% of Revenue 61.49 61.67 61.28 61.16 61.90 61.97 61.34 61.64 61.54 62.24 62.93 63.19 63.38 64.39 65.02 65.58 66.05 65.75 65.87 65.76
Gross Operating Profit 5,235 5,590 5,916 6,097 6,267 6,374 6,718 7,068 7,394 8,022 8,348 8,658 8,845 8,736 8,862 8,909 9,011 9,074 9,113 9,132
Change (%) 6.78 5.83 3.06 2.78 1.71 5.40 5.20 4.61 8.50 4.06 3.71 2.16 -1.22 1.44 0.53 1.15 0.70 0.43 0.21
% of Revenue 38.51 38.33 38.72 38.84 38.10 38.03 38.66 38.36 38.46 37.76 37.07 36.81 36.62 35.61 34.98 34.42 33.95 34.25 34.13 34.24
SG&A 3,881 4,178 4,411 4,651 4,913 5,198 5,430 5,702 5,923 6,293 6,433 6,611 6,719 6,824 7,077 7,310 7,522 7,440 7,418 7,325
Change (%) 7.65 5.56 5.44 5.65 5.80 4.46 5.01 3.88 6.25 2.22 2.77 1.64 1.55 3.71 3.29 2.90 -1.10 -0.29 -1.27
% of Revenue 28.55 28.65 28.87 29.63 29.88 31.02 31.25 30.95 30.82 29.62 28.57 28.11 27.82 27.82 27.93 28.24 28.34 28.08 27.78 27.46
R&D 0 5 6 10 13 45 51 56 71 74 80 80 75 81 79 86 93 52 48 51
Change (%) 1,013.20 37.79 61.34 25.83 239.26 15.07 9.97 25.51 4.99 8.03 -0.02 -6.99 8.32 -2.25 9.18 7.54 -44.35 -7.72 7.38
% of Revenue 0.00 0.03 0.04 0.07 0.08 0.27 0.30 0.31 0.37 0.35 0.36 0.34 0.31 0.33 0.31 0.33 0.35 0.20 0.18 0.19
OpEx 12,269 13,220 13,815 14,291 15,131 15,658 16,185 17,120 17,846 19,658 20,751 21,657 22,198 22,735 23,663 24,405 25,161 24,949 25,090 24,961
Change (%) 7.76 4.50 3.45 5.87 3.48 3.37 5.78 4.24 10.15 5.56 4.37 2.50 2.42 4.08 3.14 3.10 -0.84 0.57 -0.51
% of Revenue 90.26 90.66 90.41 91.05 92.01 93.43 93.14 92.92 92.84 92.52 92.15 92.08 91.90 92.68 93.39 94.28 94.81 94.16 93.97 93.58
Operating Income 1,324 1,363 1,465 1,406 1,315 1,101 1,192 1,305 1,376 1,590 1,767 1,863 1,955 1,796 1,674 1,479 1,378 1,547 1,610 1,712
Change (%) 2.90 7.49 -4.03 -6.46 -16.24 8.25 9.46 5.45 15.55 11.15 5.40 4.97 -8.13 -6.85 -11.59 -6.84 12.28 4.07 6.34
% of Revenue 9.74 9.34 9.58 8.95 7.99 6.57 6.86 7.08 7.16 7.48 7.85 7.92 8.10 7.32 6.61 5.72 5.19 5.84 6.03 6.42
Interest Expense -13 -11 -60 -101 -160 -212 -220 -241 -240 -232 -234 -231 -234 -239 -241 -243 -233 -249 -240 -228
Change (%) -14.37 421.18 69.37 57.50 32.66 3.69 9.40 -0.33 -3.24 1.03 -1.28 1.30 2.09 0.83 0.68 -4.01 6.72 -3.72 -4.67
% of Revenue -0.10 -0.08 -0.39 -0.65 -0.97 -1.27 -1.27 -1.31 -1.25 -1.09 -1.04 -0.98 -0.97 -0.98 -0.95 -0.94 -0.88 -0.94 -0.90 -0.86
Net Income 1,014 1,062 1,122 1,113 1,013 791 835 860 896 1,036 1,148 1,239 1,287 1,166 1,068 907 850 915 976 1,055
Change (%) 4.80 5.68 -0.83 -8.95 -21.93 5.52 2.98 4.23 15.58 10.86 7.90 3.86 -9.35 -8.43 -15.12 -6.22 7.58 6.73 8.09
% of Revenue 7.46 7.28 7.35 7.09 6.16 4.72 4.80 4.67 4.66 4.87 5.10 5.27 5.33 4.76 4.22 3.50 3.20 3.45 3.66 3.96

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista